Daily Sepsis Research Analysis
Analyzed 49 papers and selected 3 impactful papers.
Summary
Analyzed 49 papers and selected 3 impactful articles.
Selected Articles
1. A Muribaculaceae-enriched microbiota exacerbates TLR4-dependent Acinetobacter baumannii-induced hyperinflammatory sepsis.
A Muribaculaceae-enriched gut microbiota dominated by Sangeribacter muris KT1-3 primes a TLR4-hyperresponsive state that drives fatal A. baumannii sepsis. The lethal phenotype is transferable by FMT/co-housing, mediated by heat-stable <3 kDa metabolites, and operates by lowering inflammatory activation thresholds rather than impairing bacterial clearance.
Impact: This study causally links a defined microbiota configuration to TLR4-driven hyperinflammatory sepsis and identifies transferable, low–molecular-weight metabolites as mediators, offering a mechanistic basis for microbiome-based risk stratification and interventions.
Clinical Implications: Supports developing microbiome/endotype-guided sepsis risk assessment and exploring metabolite-targeted or TLR4-modulating strategies. Patient selection for TLR4 antagonism or microbiota-directed therapies may be informed by gut configuration.
Key Findings
- Muribaculaceae-enriched microbiota (dominated by Sangeribacter muris KT1-3) caused TLR4-dependent hyperinflammation and fatal sepsis in genetically identical mice.
- The lethal phenotype was transferable via fecal microbiota transplantation and co-housing, and reproduced by colonization with S. muris KT1-3.
- Fixed-dose LPS challenges and ex vivo assays showed heightened TLR4 responsiveness independent of bacterial replication.
- Single-cell transcriptomics revealed a pre-activated macrophage state; S. muris KT1-3 released heat-stable <3 kDa metabolites that potentiated systemic cytokine surges.
- Tlr4-deficient mice survived despite bacterial dissemination, indicating outcomes are dictated by inflammatory magnitude rather than pathogen clearance.
Methodological Strengths
- Causal inference via colonization, FMT, and co-housing across matched genetic backgrounds
- Convergent mechanistic validation using fixed-dose LPS, ex vivo stimulation, scRNA-seq, and Tlr4 knockout mice
Limitations
- Mechanistic findings are preclinical; human validation of metabolites and endotypes is pending
- Low–molecular-weight mediators were functionally defined but not structurally identified
Future Directions: Chemically identify the microbiota-derived metabolites, validate endotypes in human cohorts, and test microbiota/TLR4-targeted interventions in stratified preclinical-to-clinical studies.
Host survival during sepsis depends not only on pathogen burden but also on inflammatory thresholds calibrated by the gut microbiota. Here, we show that different survival outcomes were observed in genetically equivalent female C57BL/6 mouse populations depending on their specific gut microbiota configuration. A Muribaculaceae-enriched gut microbiota, characterized by the dominance of Sangeribacter muris KT1-3, predisposed mice to fatal sepsis caused by Acinetobacter baumannii via TLR4-dependent hyperinflammation. This lethal phenotype, reproduced by colonization with S. muris strain KT1-3, was transferable by fecal microbiota transplantation and co-housing. Notably, fixed-dose LPS challenge and ex vivo stimulation assays demonstrated that this configuration induces a heightened TLR4-dependent inflammatory responsiveness independent of bacterial replication. Single-cell transcriptomics revealed that these microbiota-derived factors establish a transcriptionally pre-activated macrophage state, resulting in production of excessive pro-inflammatory cytokines upon challenge. Mechanistically, S. muris strain KT1-3 releases heat-stable and low-molecular-weight (<3 kDa) metabolites that are sufficient to potentiate systemic cytokine surges under a fixed-dose endotoxin challenge in vivo, effectively lowering the host's activation threshold for TLR4-driven signaling. Tlr4-deficient mice harboring the KT1-3-enriched susceptible microbiota survived despite persistent bacterial dissemination, demonstrating that the microbiota-TLR4 axis dictates hyperinflammatory A. baumannii-induced sepsis outcomes by modulating inflammatory magnitude rather than pathogen clearance. Our results provide a conceptual framework for how specific gut microbiota configurations modulate host susceptibility and drive infection resilience.
2. Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.
PLA2G5 is induced during sepsis, drives intravascular hemolysis via lipolytic activity on erythrocyte membranes, and its genetic deletion or antibody blockade protects against lethal sepsis in mice. In humans, elevated serum PLA2G5 predicts disease severity and mortality, linking this pathway to prognostication and a potential therapeutic target.
Impact: Identifies a previously unrecognized, targetable hemolytic mechanism in sepsis with convergent animal and human data, opening avenues for PLA2G5 inhibitors or hemoglobin/heme scavenging strategies.
Clinical Implications: Supports development of PLA2G5-targeted therapeutics and use of serum PLA2G5 for risk stratification. Highlights hemolysis as a modifiable contributor to organ failure in sepsis.
Key Findings
- Organism-wide profiling identified induction of secreted PLA2G5 in colon cell types during sepsis.
- Genetic deletion of Pla2g5 and treatment with a PLA2G5-neutralizing antibody protected mice from lethal sepsis and improved iron homeostasis with increased splenic red pulp macrophages.
- Circulating PLA2G5 caused intravascular hemolysis by lipolysis of erythrocyte membranes.
- In human sepsis (bacterial, fungal, viral), elevated serum PLA2G5 predicted disease severity and mortality.
Methodological Strengths
- Mechanistic causality established via gene knockout and neutralizing antibody in multiple sepsis models
- Translational bridge with human biomarker data linking PLA2G5 levels to severity and mortality
Limitations
- Human data are correlative; interventional validation in patients is lacking
- Source cell types and kinetics in humans require further definition
Future Directions: Develop specific PLA2G5 inhibitors/antibodies for clinical testing; validate prognostic thresholds and temporal dynamics of serum PLA2G5 in prospective cohorts.
Sepsis is a systemic response to infection with life-threatening consequences such as hemolysis, a predictor of mortality risks for the disease. Here, by measuring organism-wide changes in gene expression, we discovered that the secreted phospholipase PLA2G5 is induced in colon cell types during sepsis. The genetic deletion of Pla2g5 and treatment with a PLA2G5 antibody were both associated with protection from lethal sepsis. Treatment with a PLA2G5 antibody during sepsis was associated with increased splenic red pulp macrophages and improved iron homeostasis, linking PLA2G5 to red blood cell homeostasis during sepsis. Mechanistically, bloodborne PLA2G5 led to intravascular hemolysis through its lipolytic activity on red blood cell membranes. In humans with sepsis due to bacterial, fungal, or viral infections, the serum level of PLA2G5 was elevated and predictive of disease severity and mortality. We conclude that sepsis corrupts PLA2G5 into becoming an intravascular hemolytic factor which is toxic for host red blood cells.
3. Antimicrobial peptide-induced inner membrane hyperpolarization is associated with antibiotic sensitization and attenuated MIC escalation in multidrug-resistant Gram-negative pathogens.
Sub-MIC TP2-5 creates an inner-membrane hyperpolarized state that sensitizes MDR Gram-negative bacteria to antibiotics and limits MIC escalation over serial passage, while neutralizing LPS to blunt TLR4 signaling. In a murine CLP sepsis model, TP2-5 (± meropenem) achieved 100% survival with reduced bacterial burden and cytokines.
Impact: Demonstrates a multifunctional peptide that simultaneously enhances antibiotic efficacy, restrains resistance evolution, and modulates host endotoxin responses, suggesting a promising adjuvant strategy for MDR sepsis.
Clinical Implications: Supports testing peptide adjuvants to reduce antibiotic dosing, improve efficacy against MDR pathogens, and mitigate endotoxemia. Guides design of combination regimens and surveillance of resistance trajectories.
Key Findings
- TP2-5 at sub-MIC enhanced antibiotic susceptibility of MDR E. coli in broth and 50% human serum and attenuated MIC escalation over 21-day serial passage when combined with antibiotics.
- Membrane potential assays and cryo-ET revealed inner-membrane hyperpolarization and selective interactions with LPS/anionic phospholipids rather than nonspecific permeabilization.
- TP2-5 neutralized LPS and reduced TLR4-dependent cytokine production.
- In murine CLP sepsis, TP2-5 alone or with meropenem achieved 100% survival with reduced bacterial burden and systemic cytokines.
Methodological Strengths
- Integrated biophysical, microbiological, and in vivo sepsis (CLP) models, including cryo-electron tomography
- Assessment in human serum and resistance evolution via prolonged serial passage
Limitations
- In vivo bacterial membrane potential was not measured; causality of hyperpolarization in protection remains to be proven
- Safety, pharmacokinetics, and spectrum across clinical isolates require further study
Future Directions: Define in vivo biophysical correlates, optimize dosing/PK, and advance to infection models with diverse MDR pathogens and early-phase clinical evaluation as an antibiotic adjuvant.
Antimicrobial resistance and dysregulated inflammation drive mortality in multidrug-resistant (MDR) sepsis. We evaluated the cationic peptide TP2-5 as a low-dose antibiotic adjuvant. At sub-MIC concentrations, TP2-5 enhanced antibiotic susceptibility of MDR E. coli in broth and 50% human serum, and in combination with antibiotics was associated with attenuated MIC escalation during 21-day serial passage. Membrane potential assays and cryo-electron tomography showed envelope perturbation characterized by inner-membrane hyperpolarization. This biophysical state was temporally associated with preferential interactions with lipopolysaccharide (LPS) and anionic phospholipids rather than nonspecific permeabilization. TP2-5 neutralized LPS and reduced TLR4-dependent cytokine production. In our murine polymicrobial CLP sepsis model, TP2-5 alone or with meropenem achieved 100% survival, accompanied by reduced bacterial burden and systemic inflammatory cytokines, consistent with combined antibacterial and host-directed effects, supporting a multifunctional adjuvant profile. This study did not measure bacterial membrane potential in vivo, and the causal role of hyperpolarization in protection or attenuated MIC escalation remains to be determined.